Dimerix has secured full sponsorship of the US Investigational New Drug application for its Phase 2-ready kidney drug DMX-652, setting the stage for a clinical trial targeting acute kidney injury in late 2026.
- DMX-652 IND sponsorship transferred from Mission Therapeutics to Dimerix
- Phase 2 trial for acute kidney injury planned for second half of 2026
- DMX-652 targets mitochondrial enzyme USP30 to protect kidney cells
- No approved therapies currently exist for acute kidney injury
- Transfer enhances Dimerix’s strategic control and development flexibility
Dimerix Gains Direct Control Over US Clinical Development of DMX-652
Dimerix Limited (ASX:DXB) has taken a significant step forward in its kidney disease pipeline by assuming full sponsorship of the US Investigational New Drug (IND) application for DMX-652, a Phase 2-ready asset targeting acute kidney injury (AKI). The transfer from UK-based Mission Therapeutics grants Dimerix direct regulatory engagement with the FDA and full control over the clinical development timeline and strategy for this promising renal asset.
This move marks a crucial milestone as Dimerix prepares to initiate a Phase 2 clinical trial in the second half of 2026, focusing initially on AKI associated with cardiac surgery. The company cited encouraging safety and pharmacokinetic data from an extensive Phase 1 trial, alongside compelling preclinical results, as the foundation for advancing DMX-652 into later-stage clinical evaluation.
Addressing a Critical Unmet Need in Acute Kidney Injury
Acute kidney injury is a severe condition characterised by rapid loss of kidney function, often triggered by events such as cardiac surgery, sepsis, or toxin exposure. It affects an estimated 260,000 high-risk patients annually across major markets including the US, Europe, and the UK. Currently, there are no approved treatments, and AKI carries a high risk of morbidity, mortality, and progression to chronic kidney disease.
DMX-652 operates as a selective inhibitor of USP30, a mitochondrial enzyme that impedes the removal of damaged mitochondria in kidney cells. By supporting mitochondrial quality control, DMX-652 aims to prevent kidney injury and preserve renal function. The oral, once-daily capsule formulation is designed to intervene early in the disease process, potentially altering the clinical course of AKI.
Strategic Implications and Future Opportunities for DMX-652
With IND sponsorship secured, Dimerix can directly manage FDA communications and clinical development activities, enhancing its ability to navigate regulatory pathways and optimise trial design. CEO Dr Nina Webster highlighted the broader potential of DMX-652 beyond AKI, noting its relevance across a spectrum of mitochondrial dysfunction diseases and the opportunity to explore global commercial partnerships.
The acquisition of DMX-652 also includes composition of matter patents, an FDA-approved Phase 2 trial protocol, and sufficient GMP-grade drug supply, positioning Dimerix to advance the program efficiently. This complements its lead candidate DMX-200, currently in Phase 3 for focal segmental glomerulosclerosis, reinforcing the company’s focus on kidney diseases with significant unmet medical need.
While the announcement does not provide detailed financial impacts or timelines beyond trial initiation, the transfer of IND sponsorship is a pivotal regulatory and strategic development. It sets the groundwork for Dimerix to potentially unlock value through clinical progress, partnerships, and eventual market access strategies.
Bottom Line?
Securing US IND sponsorship for DMX-652 empowers Dimerix to steer its clinical program with greater agility, but the real test will be the forthcoming Phase 2 trial outcomes and the company’s ability to translate early promise into tangible patient benefits and commercial opportunities.
Questions in the middle?
- How will the Phase 2 trial design address the heterogeneity of acute kidney injury patients?
- What partnerships or licensing deals might Dimerix pursue to maximise DMX-652’s global reach?
- How will DMX-652’s mitochondrial targeting mechanism differentiate it in a market with no current AKI therapies?